Non-myeloid Malignancies Clinical Trial
Official title:
A Phase III, Randomized, Open-label Study of Intravenous Iron Isomaltoside 1000 (Monofer®) as Mono Therapy (Without Erythropoiesis Stimulating Agents) in Comparison With Oral Iron Sulfate in Subjects With Non-myeloid Malignancies Associated With Chemotherapy Induced Anaemia (CIA)
The purpose of this study is to compare the efficacy and safety of intravenous iron therapy with oral iron therapy in patients with cancer and chemotherapy induced anaemia.
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00540696 -
Study to Develop a Screening Tool for Functional Capacity in Anemic Subjects With Nonmyeloid Malignancies Receiving Chemotherapy and Darbepoetin Alfa
|
Phase 2 | |
Terminated |
NCT00989092 -
Darbepoetin Alfa and Anemia of Cancer
|
Phase 2 | |
Completed |
NCT00118638 -
A Study of Darbepoetin Alfa for the Treatment of Anemia in Subjects With Non-Myeloid Malignancy Receiving Multicycle Chemotherapy
|
Phase 3 | |
Completed |
NCT00110955 -
Treatment of Anemia in Subjects With Non-Myeloid Malignancy Receiving Multicycle Chemotherapy
|
Phase 3 | |
Completed |
NCT00111137 -
Treatment for Patients With Non-Myeloid Malignancies Receiving Chemotherapy
|
Phase 3 | |
Completed |
NCT00401544 -
Darbepoetin Alfa With or Without Intravenous (IV) Iron
|
Phase 2 | |
Completed |
NCT00035607 -
Chemotherapy Related Anemia
|
Phase 2 | |
Completed |
NCT00239239 -
Fractionated Dosing Study: Study to Evaluate Darbepoetin Alfa for the Treatment of Anemia in Subjects With Non-Myeloid Malignancies
|
Phase 2 | |
Completed |
NCT00111462 -
Evaluating Treatment of Anemia in Subjects With Non-Myeloid MalignanciesReceiving Multicycle Chemotherapy
|
Phase 2 |